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A commentary on
NLRP3 is activated in Alzheimer’s disease
and contributes to pathology in APP/PS1
mice
by Heneka, M. T., Kummer, M. P., Stutz,
A., Delekate, A., Schwartz, S., Saecker, A.,
et al. (2013). Nature 493, 674–678. doi:
10.1038/nature11729
Alzheimer’s disease is an insidious and
dementing illness currently affecting
approximately 5 million Americans over
the age of 65, and today, someone in the
US develops Alzheimer’s disease every
68 s which is expected to drop to 33 s in
the year 2050 (Thies and Bleiler, 2013).
Although the scientific community has
learned much about the pathogenesis
of Alzheimer’s disease in recent years,
treatments to prevent progression and
reverse the effects of this disease have
yet to be developed. Current therapies
are primarily indicated for symptomatic
control, but they do not have the capac-
ity to inhibit or lead to regression of
the pathologic changes contributing to
Alzheimer’s disease. Therefore, current
research into this condition is primarily
focused on developing targeted therapies
against genes involved in the develop-
ment of Alzheimer’s disease. Currently,
an avenue that is being focused on and
should be given further attention is the
epigenetic mechanisms contributing to the
pathophysiology of Alzheimer’s disease.
The main contributing factor in the
development of Alzheimer’s disease is the
deposition of β-amyloid in the brain,
especially in the hippocampus (Heneka
et al., 2013). Previous research which
focused on chronic medical conditions
involving β-amyloid pathology has shown
that inflammatory mechanisms may be
stimulated by β-amyloid deposition (Halle
et al., 2008). Formation of β-amyloid
plaques stimulates the production of inac-
tive IL-1β, an inflammatory cytokine
(Prinz et al., 2011). However, the mecha-
nism that initiates inactive IL-1β process-
ing in Alzheimer’s disease is not clearly
defined. It was recently reported that
caspase-1-mediated processing of IL-1β
is mediated by inflammasomes in var-
ious pathological conditions (Kolliputi
et al., 2010, 2012; Fukumoto et al.,
2013). Inflammasomes, such as the NLRP3
inflammasome, detect the inflammatory
aggregates of β-amyloid and inactive IL-
1β, and respond by secreting caspase-1
(Casp-1) to activate IL-1β (Heneka et al.,
2013; Qazi et al., 2013). This leads to
the creation of an inflammatory environ-
ment around the plaque, which downreg-
ulates amyloid precursor protein (APP)
degradation, as well as decreased destruc-
tion of β-amyloid plaques by microglia
(Figure 1). Although it can be surmised
that this mechanism may contribute to
the development of Alzheimer’s disease,
its involvement has not been experi-
mentally demonstrated (Heneka et al.,
2013). NLRP3 inflammasome activation
by β-amyloid in microglia is necessary
for maturation of IL-1β and subsequent
inflammatory events; however, the role
of NLRP3 activation in Alzheimer’s dis-
ease in vivo is still unknown (Heneka
et al., 2013). A recent study by Heneka
et al. suggests that the NLRP3 inflamma-
some has a role in Alzheimer’s disease by
demonstrating increased caspase-1 expres-
sion levels in brains with Alzheimer’s
disease.
Recently, Heneka et al. conducted
a study to determine whether or not
NLRP3 inflammasome activation con-
tributes to the pathogenesis of Alzheimer’s
disease. APP/Presenilin-1 (PS1) mice,
which develop symptoms similar to
Alzheimer’s disease, were crossed with
NLRP3−/− or Casp-1−/− mice. The
quantity of cleaved Casp-1 in the brains
of the offspring was then measured in
comparison to the APP/PS1 mice. The
researchers also examined the differ-
ences in the level of spatial memory
impairment between these groups and
found that in APP/PS1/NLRP3−/− and
APP/PS1/Casp-1−/− mice, the level of
cleaved Casp-1 was markedly decreased
when compared to APP/PS1 mice, while
IL-1β levels were consistent between
the groups (Heneka et al., 2013). This
diminished Casp-1 level correlated with
preserved spatial memory function in the
APP/PS1/NLRP3−/− and APP/PS1/Casp-
1−/− mice, as opposed to the significant
spatial memory impairment seen in the
APP/PS1 mice (Heneka et al., 2013). The
researchers also compared the level of
long-term potentiation (LTP), which is
analogous to synaptic plasticity, in the
hippocampi of these mice. The APP/PS1
mice were found to have decreased hip-
pocampal synaptic plasticity, while the
hippocampal synaptic plasticity in the
APP/PS1/NLRP3−/− and APP/PS1/Casp-
1−/− mice was preserved (Heneka et al.,
2013).
The role of the NLRP3 inflam-
masome in behavioral changes and
cognitive deficiencies associated with
Alzheimer’s disease was also examined
in the study by Heneka et al. APP/PS1
underwent behavioral analysis and were
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FIGURE 1 | The diagram is a schematic representation of the role of NLRP3 inflammasome in Alzheimer’s disease.
found to have delayed habituation
and increased psychomotor agita-
tion. Conversely, APP/PS1/NLRP3−/−
mice exhibited decreased locomo-
tion and behavioral changes, further
supporting the fact that the NLRP3
inflammasome places a large part in the
development of cognitive and behav-
ioral symptoms seen in Alzheimer’s
patients.
The study by Heneka et al. also assessed
the effect of the NLRP3 inflammasome
on the phagocytic activity of microglia.
Studies have shown that large numbers of
microglia surround β-amyloid plaques in
Alzheimer’s patients. However, it is also
well known that inflammatory cytokines
inhibit microglial phagocytosis. Thus,
Heneka et al. suggested that the NLRP3
inflammasome contributes to ineffec-
tive microglial phagocytosis by leading
to increased expression of inflammatory
cytokines. After isolating microglia from
the APP/PS1 mice, APP/PS1/NLRP3−/−
mice, and APP/PS1/Casp-1−/− mice,
Heneka et al. found that microglial phago-
cytosis of β-amyloid was more efficient
as it doubled in APP/PS1/NLRP3−/−
mice and APP/PS1/Casp-1−/− mice when
compared to APP/PS1. The deficiency
in the NLRP3 inflammasome or Casp-1
did not change the overall amounts
of APP but rather reduced the lev-
els of β-amyloid aggregates. These
results provide additional evidence that
the NLRP3 inflammasome leads to
pathologic deposition and ineffective
clearing of β-amyloid in Alzheimer’s
patients.
Based on these results, the authors con-
clude that introducing therapeutic treat-
ments targeting theNLRP3 inflammasome
may have a beneficial effect on patients
with Alzheimer’s disease as NLRP3 acti-
vation may contribute to the pathogen-
esis of Alzheimer’s disease in humans.
The authors also suggest that activation of
NLRP3 enhances Alzheimer’s disease and
may be involved in synaptic dysfunction,
cognitive impairment, and the restriction
of microglial clearance functions (Heneka
et al., 2013). Therefore, human trials
should be conducted to determine the
validity of this hypothesis. The experi-
ment by Heneka et al. provides an excel-
lent model for the development of possible
future therapies for Alzheimer’s patients.
Animal and human studies examining the
safety and effectiveness of targeted NLRP3
or Casp-1 inhibitors should be further
pursued as the results reveal an important
role of the inflammatory activators NLRP3
inflammasome/caspase-1 in Alzheimer’s
disease pathogenesis and could represent
improved therapeutic treatments for mil-
lions of Alzheimer’s disease patients.
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